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Plants, People, and Partnership in Madagascar:
How Pharmaceutical Companies and Bioprospecting Ventures Must and May Positively Benefit
the Communities Whose Resources They Use
“Given the potential of traditional medicines to address issues of local access to healthcare, it is
vital to address barriers to their development, as well as to identify good practices and potential
policy interventions to mobilize the developing world’s pharmaceutical potential.” –Puri et al.
2010
Introduction:
For centuries, traditional medical practitioners around the world have understood the
tremendous wealth of medicinal power that can be found in the natural environment. In
Madagascar, traditional practitioners have both used and cared for their natural environment,
which in turn has given them a wide array of medical knowledge. According to the World Health
Organization (WHO), “approximately 80% of the world’s inhabitants rely predominantly on
traditional medicines for their primary health care” (Cao et al. 2009). Traditional medical
knowledge has relatively recently come to the attention of the international medical market. This
“recent ‘rediscovery’ of medicinally useful plants” (Sheldon et al. 1997) has lead to increases in
bioprospecting around the world. Bioprospecting is the term used now to refer to “the search for
wild species and their products, with actual and potential usefulness to humans, where the
products were commercial or non-commerical” (“Bioprospecting and Strategies” 2000).
As both the home of extraordinary biodiversity and traditional knowledge, Madagascar is
an ideal location for bioprospecting ventures. In Madagascar, there are 200 families of flowering
plants, and about 9000 out of 12000 of the flowers found on the island are endemic (Lecture: Dr.
Bernardin 6/14/11). But, the excessive and often abusive exportation of medicinal plants by
questing pharmaceutical companies may be considered partially responsible for the decline of
Madagascar’s biological diversity. Any bioprospecting ventures on the island must take the
appropriate measures to foster and conserve the natural medicinal resources of the island, both
for the Malagasy people and the global population.
However, the wealth of Madagascar’s medicinal resources is not just in the flora and the
fauna, but also in the people who live and work on the land. Approximately 1 million tons of
medical plants are exported per year, (Lecture Dr. Solo 6/20/11), at a value of about $3.59
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million dollars (Lecture Dr. Tolotra 6/20/11), but the Malagasy people themselves see very little
of the profit directly, in monetary value, or through community initiatives. Although
pharmaceutical companies and bioprospecting ventures seek to benefit much of the world’s
population by creating new and life-saving medications, the end result is too often achieved at a
high social, economic, and ecological cost. If pharmaceutical companies and bioprospecting
ventures irresponsibly exploit the natural resources of countries, like Madagascar, to produce
medicines desired by Western markets, they run the risk of depriving the people not only of their
natural resources, but also of their sources of health care. The relationship between those who
wish to export resources and the communities they exploit must be more than one of simple
economic exchange. The relationship must be a partnership, and in the long-run, both parties will
benefit. As an international conference on bioprospecting in 1997 emphasized:
“Any discussion about the industrial exploitation of forests for medicinal purposes must
address three central issues: firstly how to enhance the public’s general awareness that
environmental conservation is essential, feasible and does not compromise economic
benefits; secondly that an (administrative) structure be introduced which ensures that
indigenous communities are equitably compensated, based on the kind of quantity of
material being extracted, as well as its market value, thirdly, that indigenous knowledge
and wisdom be recognized, acknowledged, recorded and compensated and that a system
be introduced which facilitates those vital steps” (“Bioprospecting and Strategies” 2000).
This study will be an analysis of how pharmaceutical companies and bioprospecting ventures
have positively benefited the communities whose resources they use today, and what community
members would like to see improved upon in the future.
Methods:
The information analyzed in this paper comes from lecturers from the SIT: Traditional
Medicine and Health Care Systems Program, in addition to information gained from one-on-one
interviews after class. A review of the available literature on pharmaceutical medicinal plant use
and exportation is used, as well as information gained from a tour of the Societé de
Transformation Malagache Exportation (SOTRAMEX), a Malagasy research company for the
exportation of medicinal plants for international pharmaceutical companies, and Centre National
d’Application des Recherches Pharmaceutiques CNARP, a public Malagasy research center.
Twenty-five interviews with traditional practitioners, pharmacology students from the University
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of Antananarivo, and other local people were conducted to begin to understand what some
Malagasy people may want from a relationship with medicinal plant exporters. All interviewees
have been given a pseudonym for the purposes of privacy. The information gained from these
interviews should only be treated as a preliminary survey, because not enough people were
interviewed for their opinions to represent those of the Malagasy people in general. Although the
language barrier should not have had a large effect, some interview questions were asked in
French, translated into Malagasy with the help of two pharmacology students, retranslated into
French, which I then translated into English. Some of the nuances of the answers may have been
lost along the line. A general outline of the interview questions is found below, but most of the
interviews were conducted in a more free-flowing conversational format, useful to access the
diverse perspectives the interviewees had on the subject as a whole, beyond the scope of my
questions. Six of the interviews with students were conducted by passing around a form with
space for free responses. Most of these students wanted to continue to talk about the issue
beyond what they had written, so we had a brief group discussion after. The written survey was
good to allow students time to think about responses and eliminated translation errors, but that
benefit may have stood at the price of the amount of information gained from each interviewee.
INTERVIEW QUESTIONS:
1. In your opinion, how much of a
problem pharmaceutical
exportation is for the Malagasy
People: no problem, a small
problem, a large problem?
2. In your opinion, what are the
benefits of pharmaceutical
exportation of medicinal plants
for Malagasy People?
3. In your opinion, what the
pharmaceutical companies’ do to
best help the communities whose
resources they use?

1.Á votre avis, est-ce que l'exportation
pharmaceutique est (aucun problème), (un
petit problème) ou (grand problème) pour
les gens malgaches
2. Á votre avis, ce qui est les avantages
d'exportation pharmaceutique de plantes
médicinales pour les Gens malgaches?
3. Á votre avis, qu’est-ce que la mieux façon
que les compagnies pharmaceutiques
peuvent faire d’aide les communautés dont
ressources qu'ils utilisent?

Interviewee breakdown by occupation:
Pharmacology Students: 12
Traditional Healers: 4
Professors: 3
Those whose job relates to biodiversity and plant use: 3
Assorted others: 3
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Analysis
“Health and environment? They are inseparable.” –Dr. Nat Quansah, 6/30/11

The follow sections look at what several companies involved in the exportation of medicinal
plants have done to form positive community relations, and what some Malagasy people have
said they would like to see strengthened in the future.
I.

Several Pharmaceutical Companies and Bioprospecting Ventures With Programs
for Positive Community Development

A. International Cooperative Biodiversity Group (ICBG)
ICBG was founded in an “effort to integrate biodiversity conservation and drug discovery
with economic development…includ[ing] capacity building as well as research” (Cao et al.
2009). The group works in Suriname and Madagascar, producing pharmaceutical products from
medicinal plants, and includes researchers from the Missouri Botanical Garden (MBG), Virginia
Polytechnic Institute and State University (VPISU), Centre National de Recherches sur
l’Environnement, Conservation International, Centre National d’Application des Recherches
Pharmaceutiques (CNARP), Centre National de Recherches Oceanographiques (Cao et al. 2009).
A large portion of the financial support of ICBG for “conservation and development” (Cao et al.
2009) comes from Eisai Research Institute and Dow AgroSciences, which, along with BristolMyers Squibb Pharmaceutical Research Institute (BMS) from 1993–2002, then are allowed to do
“screening and isolation studies on extracts of interest to them” (Cao et al. 2009). Once the plants
are collected in Madagascar, they are brought to CNARP to be made into extracts. Once in the
dry extract form, they are shipped to Virginia Polytechnic Institute where they undergo further
testing for toxicity and bioactivity. As of 2010, ICBG has discovered approximately 80 new
compounds that showed anti-cancer activity, reaping extraordinary benefits from Madagascar’s
biodiversity (Cao et al. 2009). In return, between 1998 and 2003 ICBG implemented several
community projects, including construction of a bridge, grain storage buildings, a primary
school, “associations for market gardening and farming” (Cao et al. 2009), watering places and
wells, reforestation, dam construction, and the creation of several Protected Areas (Cao et al.

4

Rebecca Slotkin
Research Paper: SIT Madagascar
7/8/11

2009). Recently, ICBG also helped to establish an anti-malarial research laboratory at CNARP
and trained “several Malagasy scientists in botany, microbiology, and chemistry” (Cao et al.
2009). With its conservation and capacity building efforts, ICBG can stand as an example of the
diverse and relatively low cost projects that international pharmaceutical companies and
bioprospecting ventures can do to create a more balanced relationship with the communities
whose resources they so benefit from.
B. Societé de Transformation Malgache Exportation (SOTRAMEX)
SOTRAMEX, whose clients are international pharmaceutical companies, mainly chooses the
plants it collects through a review of the available literature under the direction of its clients, but
also works with local traditional medical practitioners when available (SOTRAMEX tour
06/22/11). The plants are collected by local collectors, who are paid at minimum 500 Ar. per kilo
of plant collected, about 25 cents, a wage that they standardize against the average physical
laborer’s wage of 5,000 Ar. per day, about $2.5 dollars. They raise the price per kilo according to
the value of the plant collected (SOTRAMEX tour 6/22/11). Once the plants reach the research
center, they undergo a process of extraction, filtration, evaporation, and a freezing process to
prepare the plant chemicals for testing (SOTRAMEX tour 6/22/11). SOTRAMEX is first and
foremost a business, emphasizing the maximization of profit and the fulfillment of its clients
desires, but it has reportedly built twenty primary schools around Madagascar and has run
several local community initiatives, such as supplying potable water (SOTRAMEX tour
6/22/11). Although its community initiatives are a good step in building positive community
relationships, none of their products, their research, or their profit is accessible to the local
community.
C. Institut Malgache de Recherches Appliquées (IMRA)
IMRA was founded in 1958 by Dr. Albert Rakoto-Ratsimamanga using the royalty money
from his previous discovers (Puri et al. 2010). After his death in 2001, IMRA has been headed by
his wife, Suzanne Ratsimamanga. The institute’s goal is both to research and develop affordable
drugs and “to promote Malagasy culture and preserve local biodiversity” (Puri et al. 2010).
IMRA is divided into four sections: (1) the research and development department: a non-profit
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department that also trains Malagasy researchers by collaborations with universities in
Madagascar and abroad; (2) the biodiversity department, which has a garden and “lab for
collecting and preserving endangered medicinal plants” (Puri et al. 2010); (3) production, quality
control, distribution and exportation department for drugs and cosmetics: for-profit division
separately incorporated as Soamadina Limited; (4) a health clinic with free medical consultations
for Malagasy people (Puri et al. 2010). The majority of IMRA’s revenue, about 60%, comes
from exports, mainly to European partners, and the rest comes from local sales in hospitals, its
own clinic, and pharmacies around the country (Puri et al. 2010). But, IMRA would not be viable
without the profit generated from its exportation of medicinal plants, and the profits gained from
exportation help keep the prices of their local products affordable, but maybe not affordable
enough (Puri et al. 2010). IMRA’s commitment to working with local traditional healers and
using some of their resources to the benefit of the Malagasy people demonstrates one way that
local and international interests can be successfully combined.
D. Centre National d’Application des Recherches Pharmaceutiques (CNARP)
Like IMRA, CNARP is also a Malagasy research institute, but a public one, partially funded
by the state. CNARP’s goal is to reinforce and valorize the traditional medicine system and
scientifically prove the efficacy of traditional remedies. CNARP works with the Ministry of
Health, OMS, and ICBG and its partners. The center focuses on the local market working to
synthesize products for sale in Madagascar in priority areas such as stomach and respiratory
illnesses, and malaria. They also have a laboratory for synthesizing their own pharmaceutical
products, and an endangered plant garden, which experiments with the possibilities of cultivation
of certain species. In collaboration with international groups, they have helped with a green
education program in primary school students, but, as the director laments, it does not include the
concept of sustainable or traditional use of natural resources. CNARP’s profit is only 2% of their
budget, and relies on partnerships with ICBG and other international pharmaceuticals interested
in malaria and essential oil research. Without too much clout within the government, especially
during political crises, it is often hard for CNARP to get its products to market. However, as an
organization devoted to benefiting the Malagasy people, CNARP is an example of what is
possible for other Malagasy researchers and international bioprospectors (CNARP tour 6/24/11).

6

Rebecca Slotkin
Research Paper: SIT Madagascar
7/8/11

II.

Advantages of Positive Community Development

The phrase “international pharmaceutical company” has often become synonymous with
some equivalent of “the big bad wolf,” but this is not always, and does not have to be, the case.
Medicinal plant research and development institutes, both internationally and in Madagascar, do
create sources of local employment and a source of revenue for the country. In Madagascar, the
government receives a royalty for each new plant exported, and collectors, cultivators, and local
researchers also receive varying levels of income from the industry (Nat Quansah Interview
6/28/11). Beyond economic benefits, the drugs developed by bioprospecting entities have been
beneficial in curing or reducing the death toll of many diseases from cancer to malaria. For the
people of Madagascar, medications developed from local biodiversity are “at worst five to ten
times less expensive than pharmaceutical products” (Nat Quansah, Lecture 6/30/11), giving local
people not a replacement for their well tested traditional remedies, but a complement.
Using biodiversity in the development of medications is also beneficial because it
“reinforces people’s links with nature” (Nat Quansah, Lecture 6/30/11), giving then a tangible
and immediate reason for its conservation. However, if we are to continue to access the resources
we desire, conservation is vitally important. As Sheldon et al. writes, “the incentives for
preserving plant populations falls behind the immediate monetary incentives of highly profitable
medications and the rush to produce before the patent expires” (Sheldon et al. 1997). In the case
of Prunus Africana, a tree whose bark is a major component in medications that treat benign
prostatic hyperplasia, excessive and careless exploitation put the once common tree on the
endangered species lists (Dr. Solo 6/20/11). When asked about Prunus africana, Dr. Solo shakes
his head. He says the tree used to grow every kilometer or so, and now there are very, very few
(Dr. Solo Interview 6/20/11). With the demand for the bark of the tree created by the
international market, people began cutting down the whole tree and stripping it, rapidly depleting
the natural resource and threatening the survival of the once common tree (Nat Quansah
Interview 6/18/11). According to one unverified source, SOTRAMEX paid so much money for
the collection of the bark because of its highly profitable exportation to Italy that its collectors
carelessly over-exploited the tree to near extinction (CNARP tour 6/24/11). Although they may
not directly have a hand in depleting the biodiversity of the countries they harvest their resources
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from, pharmaceutical companies create a concentrated demand on several targeted species, such
as the Prunus africana and must ensure that there are adequate mechanisms to prevent the loss of
the biodiversity that both they and the local community relies upon. That being said, simple
preservation of the local biodiversity is not enough. Too often, the creation of untouchable nature
preserves prevents local access to their own resources (Nat Quansah Lecture 6/30/11). Depriving
local practitioners from their resources is harmful both to positive community relations and to
local health. Companies that wish to maintain their access to both local resources and knowledge
must work towards conservation and sustainable use of their resources, whether those resources
are plants or the knowledge of their uses.
Because of its important place in local and international health, medicinal plant research,
exportation, and development must be conducted in a responsible and renewable manner for both
the present and the future. In the long run, all parties involved will benefit. How are these
benefits seen? Here is one story: Brian, who visited IMRA under the advice of a family member,
felt his experience there was a good one. He was thrilled that his medication came from natural
sources; croc oil for his cough, some leaves for his stomach. The only problem, he said, was that
going there takes the whole afternoon. He came at 1200 and left at 1700. Although the
consultation is only a small fee, he said, the medication itself was really expensive. He paid
60,000AR for the medication, a price too expensive for many Malagasy people (Brian, Interview
2011).
One pharmacology student spoke of Madeglucyl, IMRA’s star product, a drug effective
for reducing the amount of insulin needed to manage type I and II diabetes (Puri et al. 2000).
Madeglucyl is only sold in Madagascar, but is available on the international market now as
Glucanol ForteTM (Puri et al. 2000). The only problem is that since the international
pharmaceutical company that markets it abroad has changed the name, none of the international
sales revenue goes back to IMRA, the first to manufacture the drug (Ellen, Interview 2011).
Perhaps if IMRA and other local institutions could sell their products overseas, their increased
profit margin would allow them to lower their local drug prices to a more affordable range. It is
easy to see the cascading impacts of international pharmaceutical exportation of Madagascar’s
resources. Once the remedies leave the country, there is little return for the Malagasy people.
But, the exportation companies need IMRA and other Malagasy institutes like it just as much as
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IMRA needs the exportation companies. Due to governmental regulations, only Malagasy
companies are allowed to do the medicinal plant collection and extraction (Nat Quansah,
Interview 6/28/11), and, by the same token, one student says that the Ministry of Health makes it
difficult for Malagasy companies to get the AMM certification they need to sell their product
overseas if they had the resources to synthesize it (Sadie, Interview 2011). International
pharmaceutical companies stand to benefit in working with partners like IMRA, which in turn
benefits the Malagasy people, because positive community relations increase the likelihood of
successful bioprospecting.
As Puri et al. writes, “’capacity-building’ may prove costly in the short-term, but is vital
in the long-term to ensure that local scientists possess the ability to conduct significant research”
(Puri et al. 2010). Increasing local research capacity, or “invest[ing] in human capital” (Puri et al.
2010) will benefit international companies as well because they must use local sources like
SOTRAMEX, IMRA, and CNARP to perform preliminary analysis and collection of medicinal
plants of interest. Building relationships with local traditional healers and community members
also saves time and money. One small example of this principle is as follows: a trip to a healer
itself may be viewed by both the healer and the patient as part of the healing process. As Puri et
al writes, while “a visit may facilitate a ‘hoped for result’ (i.e. a cure that has a biomedical basis),
it always affects an ‘expected result’ (i.e. a confirmation of the illness which in turn reinforces
the worldview of the given society)” (Puri et al. 2010). A researcher who simply demands to
know what medicinal remedies are given in which circumstances and leaves, not only misses an
opportunity to form a constructive and mutually beneficial relationship, but also may miss that
“the cure [that the traditional remedy] elicits could be culturally specific and have no biological
basis” (Puri et al. 2010). While traditional healers are a tremendous source of knowledge, they
are also people who must be treated with respect, equality and dignity, not as encyclopedias to be
opened and closed at will. Certainly, the developing positive community relations, creating
mechanisms to respectfully conserve local biodiversity and knowledge, and increasing local
capacity stands to benefit to all parties involved in medicinal plant research and drug
development.
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III.

Some Malagasy Voices: What Companies Can Do To Best Help the Communities

As those who wish to see increased benefits from the exportation of their natural
resources, the Malagasy people themselves have the right and the responsibility to decide what
kind of benefits would be most welcome. The data analyzed here is compiled from 25 Malagasy
voices (see data table below for the full analysis). Many of those interviewed saw the benefits of
medicinal plant exportation as primarily to help people around the world. As one man said,
“nature serves life, we cannot guard our resources, it’s egotistic” (Mr. Nick, Interview 2011).
Only one of the traditional healers interviewed saw exportation of medicinal plants as a problem
that might threaten biodiversity or the community; the rest saw no effect of exportation on their
lives or practice. All the traditional healers said that they would be more than happy to share
their knowledge of medicinal plants with anyone who was interested, hoping to benefit mankind
(Aggregate Interviews 2011). Other top benefits included the creation of jobs and sources of
income, and the validation and advancement of medical knowledge (Aggregate Interviews
2011).
Despite the benefits that many of the
interviewers acknowledged, ranked from large,
small or no problem, the majority of all those
interviewed believed that the exportation of
medicinal plants was a large problem for the
Malagasy people (Aggregate Interviews 2011).
Why? The interviewees cited three issues most
frequently: the profit from exportation falls into the
hands of very few and the majority of Malagasy
people do not see profit, traditional medicines are
exported and pharmaceuticals are imported and
sold at a high price, and exportation regulations are not sufficient/equal: not everyone can export
(Aggregate Interviews 2011).
While the issues of unequal exportation regulations and the other problems cited are large
hurdles, the interviewees were also able to see ways that international bioprospectors could
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ameliorate the situation. One fortunate man has figured out how to circumvent the issue of
unequal exportation. Steve plans on cultivating and selling Ravinstara, a plant whose leaves
produce a coveted essential oil, to European pharmaceuticals. According to his calculations, he
stands to make a profit of 229,800 Euros in four years when his crop is ready, making him a
millionaire in Madagascar. To start his venture, he created a Society (as SARL, Society
Responsible Limite), a necessary step for exporters, opened a bank account, and will be buying
the appropriate extracting technology for 70,200 Euro. He says it’s a simple process and
foreigners come to Madagascar to do it all the time. Fortunately he has both the knowledge to
make the extract and the capital to purchase it (Steve Interview 2011). However, while this
dream may be possible for him, it is an unimaginable reality for most medicinal plant cultivators
because of the comparatively immense start up price, and lessening the inequalities in the system
of exportation would enable more people gain the benefits of their resources.
By far the most desired change to the current system would be for the international
pharmaceutical companies to help increase the scientific infrastructure, helping Malagasy
researchers develop their own pharmaceutical products (Aggregate Interviews 2011). As Dr.
Tolotra says, Madagascar spends $200 million US dollars on medications produced elsewhere
(Dr. Tolotra Lecture 6/20/11),
and pharmaceutical products are
often too expensive for most
people to afford. Increasing the
capacity of local research
companies would decrease
Madagascar’s reliance on
imported medications and
increase health care availability.
At the same time, increasing the capacity of local companies will increase their ability to
investigate and sell new medications to international companies.
After increasing research capacity of local institutes, interviewees suggested educating
the Malagasy people about their wealth of resources and the necessity of their conservation;
communicating with the community members about the importance of their environment as a
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source of food, shelter, income, and health (Aggregate Interviews 2011). In this way, education
would build the capacity of the people themselves to value and conserve their natural resources.

Conclusion:
As it stands, the system of international exportation and bioprospecting ventures already
has several benefits for the community, but can and must be improved upon. Future discussion
should increase the scope of the data collected, interviewing more students as their status as
future pharmacologists, and analyzing more exportation companies. Companies such as ICBG,
IMRA, and CNARP, and others not analyzed here, which follow their model, do work to
establish positive community relationships. SOTRAMEX and other more business oriented
companies would ultimately benefit both themselves and the communities they work with by
following these models. All international exportation and bioprospecting companies might
consider the voices of the Malagasy people interviewed above, taking into account their
suggested solutions and believed issues with the current situation. Just as establishing positive
community relations benefits all parties involved, so too does improving those relations. As Nat
Quansah says, we must work together not just for the present, not just for the future, but for “the
today to come” (Nat Quansah, Lecture 6/30/11).
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Sheldon, Jennie Wood, Michael J. Balick, Sarah A. Laird. “Medicinal Plants: Can Utilization
and Conservation Coexist?” Advances in Economic Botany Volume 12. ed. Charles M.
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SOTRAMEX. Programmed Tour of Facilities. 6-22-11
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Rebecca Slotkin
Research Paper: SIT Madagascar
7/8/11

Solo Dr. Lecture: Histoire Politique de Madagascar Avant et Pendant la Colonialisation. 06-2011. Translation : Rebecca Slotkin
Solo Dr. Interview: 6-20-11.
Steve Interview, June 2011

15

